Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy

Klement, Rainer J.; Hoerner-Rieber, Juliane; Adebahr, S.; Andratschke, Nicolaus; Blanck, Oliver; Boda-Heggemann, Judit; Duma, Marciana-Nona; Eble, Michael J.; Eich, H C; Flentje, Michael; Gerum, S.; Hass, Peter; Henkenberens, Christoph; Hildebrandt, Guido; Imhoff, Detlef; Kahl, Klaus Henning; Klass, Natalie Désirée; Krempien, Robert; Lohaus, Fabian; Petersen, Cordula; Schrade, E.; Wendt, Thomas; Wittig, Andrea; Gückenberger, Matthias

doi:10.1016/j.radonc.2018.02.016

Cited by 40 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other single-arm, retrospective registries have provided evidence on the clinical effectiveness of SABR in patients with oligometastatic cancer (19)(20)(21)(22). They reported one-and two-year OS rates ranging from 70-74% and 47-60%, respectively, with both outcomes lower than our study findings, however our cohort has a very short follow-up and only two thirds of patients had visceral metastases.…”

Section: Discussionmentioning

confidence: 99%

Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study

Chalkidou

Macmillan

Grzeda

et al. 2021

The Lancet Oncology

162

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study

Chalkidou

Macmillan

Grzeda

et al. 2021

The Lancet Oncology

162

View full text Add to dashboard Cite

show abstract

“…These technological advances of SBRT and its improved accuracy translated into an improved therapeutic ratio with low risk of toxicity and simultaneously high rates of local tumor control. Safety and efficacy of high-dose SBRT was demonstrated in metastases of histology previously assumed as radioresistant (Guckenberger et al, 2016;Klement et al, 2018). For pulmonary oligometastases of NSCLC, a matched pair analysis reported the identical outcome of SBRT and surgical metastasectomy and similar promising results of SBRT have been described for other frequent oligometastases locations, such as the liver, adrenal gland, bone metastases, and lymph node metastases.…”

Section: Technology To Advance Cancer Care: the Example Of Sbrt For Omentioning

confidence: 62%

Technology‐driven research for radiotherapy innovation

et al. 2020

View full text Add to dashboard Cite

Technology has a pivotal role in the continuous development of radiotherapy. The long road toward modern ‘high‐tech’ radiation oncology has been studded with discoveries and technological innovations that resulted from the interaction of various disciplines. In the last decades, a dramatic technology‐driven revolution has hugely improved the capability of accurately and safely delivering complex‐shaped dose distributions. This has contributed to many clinical improvements, such as the successful management of lung cancer and oligometastatic disease through stereotactic body radiotherapy. Technology‐driven research is an active and lively field with promising potential in several domains, including image guidance, adaptive radiotherapy, integration of artificial intelligence, heavy‐particle therapy, and ‘flash’ ultra‐high dose‐rate radiotherapy. The evolution toward personalized Oncology will deeply influence technology‐driven research, aiming to integrate predictive models and omics analyses into fast and efficient solutions to deliver the best treatment for each single patient. Personalized radiation oncology will need affordable technological solutions for middle‐/low‐income countries, as these are expected to experience the highest increase of cancer incidence and mortality. Moreover, technology solutions for automation of commissioning, quality assurance, safety tests, image segmentation, and plan optimization will be required. Although a large fraction of cancer patients receive radiotherapy, this is certainly not reflected in the worldwide budget for radiotherapy research. Differently from the pharmaceutical companies‐driven research, resources for research in radiotherapy are highly limited to equipment vendors, who can, in turn, initiate a limited number of collaborations with academic research centers. Thus, enhancement of investments in technology‐driven radiotherapy research via public funds, national governments, and the European Union would have a crucial societal impact. It would allow for radiotherapy to further strengthen its role as a highly effective and cost‐efficient cancer treatment modality, and it could facilitate a rapid and equalitarian large‐scale transfer of technology to clinic, with direct impact on patient care.

show abstract

“…SBRT has been shown to be an efficacious treatment for patients with oligometastatic cancer in both retrospective and prospective reports [1,4]. In 2019, the Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Disease (SABR-COMET) trial was the first known prospective trial showing a clinical benefit of SBRT in the oligometastatic setting [1].…”

Section: Discussionmentioning

confidence: 99%

Safety of Stereotactic Body Radiation Therapy for Seven Ipsilateral Lung lesions

Bernard¹,

Critchfield²,

Kudrimoti³

2020

Cureus

View full text Add to dashboard Cite

show abstract

Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy

Cited by 40 publications

References 30 publications

Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study

Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study

Technology‐driven research for radiotherapy innovation

Safety of Stereotactic Body Radiation Therapy for Seven Ipsilateral Lung lesions

Contact Info

Product

Resources

About